BR112023013247A2 - Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos - Google Patents

Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos

Info

Publication number
BR112023013247A2
BR112023013247A2 BR112023013247A BR112023013247A BR112023013247A2 BR 112023013247 A2 BR112023013247 A2 BR 112023013247A2 BR 112023013247 A BR112023013247 A BR 112023013247A BR 112023013247 A BR112023013247 A BR 112023013247A BR 112023013247 A2 BR112023013247 A2 BR 112023013247A2
Authority
BR
Brazil
Prior art keywords
cells
steroid
human
adcs
antibody
Prior art date
Application number
BR112023013247A
Other languages
English (en)
Inventor
Alexander Koval
Anna Kuta
Catherine Carriere
Dmitry Borkin
Dov Pechenick
Erin Clark
Jay Rothstein
Jieyu Zhou
Julio Medina
Kierstin Bell
Labros Meimetis
Maria Day
Michael Molloy
Nicholas Schwertner
Maganlal Loriya Rajeshkumar
Sergey Seregin
Sheng Sun
Shibhani Rajanna
Sravan Thummanapelli
Toni Kline
Xin Huang
Yalin Guo
Yingcai, (Ian) Wang
Original Assignee
Immunext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunext Inc filed Critical Immunext Inc
Publication of BR112023013247A2 publication Critical patent/BR112023013247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos. glicocorticosteroides, ligantes do mesmo e conjugados de anticorpo-fármaco (adc) compreendendo anticorpo ou fragmento de anticorpo que se liga a antígeno expresso em células imunes, opcionalmente antígeno expresso em células imunes humanas. em alguns casos, adcs compreendem anticorpo anti-vista humano (supressor de ativação de células t contendo imunoglobulina de região v (1)) ou fragmento de anticorpo de ligação ao antígeno anti-vista que se liga a células que expressam vista em ph fisiológico com uma meia-vida sérica curta (˜ 24-72 ou 24-48 ou 12-24 horas ou menos em um roedor knockin com vista humano ou (˜ 1-3,5 dias ou menos em um primata humano ou não humano). em alguns casos, esses adcs têm rápido início de ação e são potentes por duração prolongada, pois são internalizados de forma muito eficaz pelas células imunes em grandes quantidades, onde são clivados, liberando grandes quantidades de carga útil de esteroides ativos. uso de tais adcs e novos esteroides para tratamento de condições autoimunes, alérgicas e inflamatórias. métodos para reduzir os efeitos colaterais adversos e/ou aumentar a eficácia dos agonistas do receptor de glicocorticoides usando tais adcs para distribuir seletivamente esses agentes anti-inflamatórios às células imunes alvo, como monócitos, neutrófilos, células b, células t, tregs, eosinófilos, células nk, macrófagos, células mieloides, et al., e em particular células mieloides, reduzindo assim a toxicidade potencial para células não alvo.
BR112023013247A 2021-01-07 2022-01-07 Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos BR112023013247A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202163134811P 2021-01-07 2021-01-07
US202163138958P 2021-01-19 2021-01-19
US202163178378P 2021-04-22 2021-04-22
US202163186447P 2021-05-10 2021-05-10
US202163188499P 2021-05-14 2021-05-14
US202163246941P 2021-09-22 2021-09-22
US202163251939P 2021-10-04 2021-10-04
US202163271023P 2021-10-22 2021-10-22
US202163271554P 2021-10-25 2021-10-25
US202163284886P 2021-12-01 2021-12-01
US202163290100P 2021-12-16 2021-12-16
PCT/US2022/011687 WO2022150637A1 (en) 2021-01-07 2022-01-07 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF

Publications (1)

Publication Number Publication Date
BR112023013247A2 true BR112023013247A2 (pt) 2023-10-03

Family

ID=82358345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023013247A BR112023013247A2 (pt) 2021-01-07 2022-01-07 Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos

Country Status (10)

Country Link
EP (1) EP4271387A1 (pt)
JP (1) JP2024502360A (pt)
KR (1) KR20230144129A (pt)
AU (1) AU2022205664A1 (pt)
BR (1) BR112023013247A2 (pt)
CA (1) CA3203533A1 (pt)
IL (1) IL304059A (pt)
MX (1) MX2023008096A (pt)
TW (1) TW202241451A (pt)
WO (1) WO2022150637A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500816A (zh) * 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139369A (en) * 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
CA3025377A1 (en) * 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Also Published As

Publication number Publication date
IL304059A (en) 2023-08-01
AU2022205664A1 (en) 2023-08-17
KR20230144129A (ko) 2023-10-13
JP2024502360A (ja) 2024-01-18
MX2023008096A (es) 2023-09-22
WO2022150637A1 (en) 2022-07-14
CA3203533A1 (en) 2022-07-14
TW202241451A (zh) 2022-11-01
EP4271387A1 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
BR112023013247A2 (pt) Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos
Wang et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events
JP5951615B2 (ja) Ｔｌｒアゴニストの治療用途および組み合わせ治療
Brandish et al. Development of anti-CD74 antibody–drug conjugates to target glucocorticoids to immune cells
Préville et al. Mechanisms Involved in Antithymocyte Globulin Immunosuppressive Activity in a Nonhuman Primate Model 1
Saber et al. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
de Fátima Pereira et al. The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies
Stebbings et al. “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics
Weissmann et al. The role of lysosomes in immune responses
Arnoldi et al. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy.
Norman et al. PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1
Kyriakidis et al. Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies
Chan et al. Angiotensin II causes β-cell dysfunction through an ER stress-induced proinflammatory response
Brenneman et al. Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity
Bhatt et al. CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas
Jadoon et al. Immunotherapy in multiple myeloma
Ho et al. Current and novel therapies in acute GVHD
Radhakrishnan et al. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation
Spies et al. Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells
Los-Arcos et al. Risk of infection associated with new therapies for lymphoproliferative syndromes
Yang et al. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation
Blinkenberg et al. Monoclonal antibodies for relapsing multiple sclerosis: a review of recently marketed and late-stage agents
Kloster-Jensen et al. Treatment with tacrolimus and sirolimus reveals no additional adverse effects on human islets in vitro compared to each drug alone but they are reduced by adding glucocorticoids
Bradding et al. Biology of mast cells and their mediators
Pranzatelli et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus